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Venous thromboembolism (VTE), including deep 
vein thrombosis (DVT) and pulmonary embolism 
(PE) are a set of life-threatening complications as-
sociated with surgery5,9).  VTE has been reported 
as one of the most important potentially prevent-
able conditions which increase morbidity and mor-
tality11).  The risk of VTE varies according to the 
patients’ related thrombotic risk factors, such as 
age, sex, obesity, cancer, familial history, infection, 
heart disease, respiratory disease, hormone treat-
ment, and poor functional status7,16).  Major ab-
dominal and pelvic surgery for cancer, puts these 
patients at a high risk of post-operative VTE12,14).
The current American College of Chest Physi-
cians (ACCP 2012) guideline, reported that general 
and abdominal-pelvic surgery patients, at high risk 
for VTE (～6.0%) were recommended pharmaco-
logical prophylaxis with low-molecular weight hep-
arin (LMWH) or low-dose unfractionated heparin 
(UFH), in addition to mechanical prophylaxis 
with elastic stockings (ES) and intermittent pneu-
matic compression (IPC)5,6).  The Caprini score is 
widely accepted for the identification of clinically 
high risk patients for VTE (score ≧5)5); however, 
the majority of patients who underwent gastroen-
terological surgery for malignant tumor are classi-
fied as a high risk group.  The guidelines for VTE 
prophylaxis in Japan also categorized patients 
undergoing major cancer surgery as a high-risk 
group, for whom thrombo-prophylaxis with IPC or 
low-dose UFH was recommended.
Despite these recommendations, pharmacologi-
cal prophylaxis after gastroenterological surgery 
was not widely administrated, especially in Japan, 
because of concerns about bleeding complications 
and epidural hematoma after epidural anesthesia. 
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(range, 21-93).  Median body mass index was 21.9 
(range 14.5-36.5).  Open surgery was performed in 
59 cases and laparoscopic surgery was performed 
in 97 cases.  Details of the operative procedures 
are listed in Table 1.
Original risk classification of VTE in this 
study
Original risk classification of VTE in this study 
is demonstrated in Fig. 1. In detail, we defined the 
highest risk factors as the presence of VTE, a his-
tory of VTE, application of anticoagulant therapy 
and presence of a blood coagulation disorder.  Ma-
lignant disease, obesity (body mass index, BMI: 30 
or more), poor performance status (3 or 4), delayed 
ambulation, and age (60 years or more) were de-
fined as 2 points of risk factor; and obesity (BMI: 
28 to 30), age (40 to 60 years old), long operation 
time (more than 3 hrs), pelvic surgery, application 
of hormonal therapy, presence of varicose vein, 
heart failure, placement of central venous catheter 
(CV), and preoperative chemotherapy were defined 
as 1 point of risk factor.  The highest risk group 
was defined as the patients who had any one of the 
highest risk factors.  The high risk group was de-
fined as the patients who had 6 points or more of 
risk factors, and the low risk group was defined 
as the patients who had 5 points or fewer of risk 
factors.  These risk factors for VTE were based on 
the Caprini score and the Japanese VTE guideline.
Protocol of postoperative prophylaxis based on 
the original risk classification of VTE
VTE physiologic prophylaxis, including postop-
erative ES and IPC, was routinely administered to 
In order to minimize this disadvantage, more se-
lective pharmacological prophylaxis is needed 
based on the risk classification, which can identify 
the patients at high risk for VTE.
In this study, we tried to establish the original 
risk classification to determine the indication of 
postoperative pharmacological prophylaxis for se-
lected patients at high risk for VTE.  We investi-
gated the safety and efficacy of prophylaxis based 
on this risk classification of VTE after lower ab-
dominal surgery.
PATIENTS AND METHODS
Patients
This study was the retrospective study using 
collected clinical data.  One hundred and fifty-six 
consecutive patients who underwent elective lower 
abdominal surgery were enrolled (January 2013 to 
March 2014, Hiroshima University Hospital). 
Ninety male and sixty-six female patients were in-
cluded in this study, with a mean age of 66 years 
Table 1. Operative procedures (n = 156)
Open/Laparoscopic 59/97
Colectomy 85
Proctectomy 40
Stoma closure 14
Tumor resection 4
Resection of small intestine 4
Repair of incisional hernia 4
Stoma creation 2
Total colectomy 1
Bypass 1
Incisional biopsy 1
Fig. 1. Original risk classification of venous thromboembolism (VTE) in this study. 
BMI, body mass index; CV, central vein; UFH, unfractionated heparin; LMWH, low-molecular weight heparin
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analyzed by the chi-square test, Mann-Whitney U 
test, and paired t-test.  In all analyses, statistical 
significance was set at a p value less than 0.05. 
All data are expressed as mean values ± standard 
deviation.  All statistical analyses were performed 
using the IBM SPSS Statistic 20.0 software pack-
age.
RESULTS
Risk classification and validation
Among the 156 patients, 16 patients were classi-
fied in the highest risk group, 50 cases were clas-
sified in the high risk group, and 90 cases were 
classified in the low risk group, based on the orig-
inal risk classification.  The details of risk factors 
for VTE in this study are demonstrated in Table 2.
Firstly, we attempted to verify the validity of the 
original risk classification by using the Caprini score. 
The Caprini scores of the three groups are demon-
strated in Fig. 2. Caprini scores of the highest and 
all the patients.  Postoperative pharmacological 
prophylaxis was indicated for the patients in the 
highest risk group and the high risk group. 
Principally, continuous injection of UFH was ad-
ministered to the patients of the highest risk 
group, and subcutaneous injection of enoxaparin 
20 mg twice daily was administered to the pa-
tients in the high risk group.  Pharmacological 
prophylaxis was started 24-36 hrs after surgery, 
with the attending doctor’s permission, and con-
tinued for 7 days.  UFH was continuously infused 
and the value of APTT was maintained between 
1.5 to 2 times from the reference value.  For the 
patients with high risk of postoperative bleeding, 
on the attending doctor’s decision, pharmacologi-
cal prophylaxis was not applied, irrespective of the 
risk classification.  In the patients who received 
pharmacological prophylaxis, postoperative pain 
control was administered through intravenous an-
algesia by opioid in place of epidural anesthesia.
Assessment
Short-term outcomes of the pharmacological pro-
phylaxis based on the original risk classification of 
VTE, including thrombotic and bleeding complica-
tion, were assessed.  In this study, postoperative 
examinations such as computed tomography and 
ultrasonography were not assessed to detect as-
ymptomatic VTE.  Therefore, we monitored periop-
erative fibrin related markers (D-dimer and fibrin 
degradation products (FDP)), and assessed the effi-
cacy of pharmacologic prophylaxis based on the 
original risk classification in the view of these 
markers.
Before surgery, all the patients were provided 
with a detailed explanation of the risks and writ-
ten informed consent was obtained from each pa-
tient.  The complications were graded according to 
the method described by Dindo et al4).  Complica-
tions with a grade above II were categorized as 
morbid.  The postoperative ambulation day was 
defined as the first day on which the patient spent 
50% or more of the daytime in the standing or sit-
ting position.
Measurements in plasma samples
Blood samples were obtained from peripheral 
veins early in the morning, on the preoperative day, 
and on postoperative days(POD)1, 3, and 7. D-dimer 
(LIAS AUTO® D-dimer NEO, Sysmex, Kobe, Japan) 
and FDP (LIAS AUTO® P-FDP, Sysmex, Kobe, 
Japan) levels were measured by the latex aggluti-
nation method using a commercial immunoassay 
kit.  All tests were performed on a Sysmex CS5100 
analyzer (Sysmex, Kobe, Japan).  The standard val-
ue amounted to ≦1 μg/ml for D-dimer and ≦5 μg/ml 
for FDP.
Statistical analyses
Statistical significance between the groups was 
Table 2. Risk factors for VTE in the study population
Risk factors n
High age (60 years old or more) 125
High age (40 to 59 years old) 26
Malignant disease 135
Estimated operative time (3 hours or more) 126
Pelvic surgery 32
Obesity (BMI: 30 or more) 2
Obesity (BMI: 28 to 30) 9
Preoperative chemotherapy 6
Poor performance status 5
Placement of CV catheter 5
Application of hormone therapy 3
Presence of varicose vein 2
VTE, venous thromboembolism; BMI, body mass index; 
CV, central vein
Fig. 2. The validation of the original risk classification 
by using Caprini score.
Caprini scores of the highest and the high risk groups 
were significantly higher than that of the low risk group 
(p < 0.0001).
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tion of anticoagulant therapy was postoperative day 
2 (range, 1-5) in the high risk group and 2 (range, 
0-3) in the highest risk group.
Outcome
There was no symptomatic pulmonary embolism 
in this study population.  Post-operative bleeding 
complications, including subcutaneous bleeding 
and gross hematuria, occurred in 3.4% (2 of 59) of 
the patients (subcutaneous bleeding and gross he-
maturia).  These bleeding complications were all 
classified as Grade 1, and major bleeding compli-
cations requiring blood transfusion or re-operation 
did not occur.  There were no significant differenc-
es in the first flatus day (p = 0.37), the first defeca-
tion day (p = 0.54), the occurrence of postoperative 
complication (p = 0.11), and the decline of Hb lev-
els (more than 2 g/dl) (p = 0.65) among the three 
groups (Table 3).  However, there were significant 
differences in the postoperative ambulation day (p 
< 0.01) and postoperative hospital stay (p < 0.01).
There were no significant differences in the 
administration of routine oral Non-Steroidal Anti-
Inflammatory Drugs (NSAIDs) (p = 0.32), rescue 
use of oral NSAIDs (p = 0.90), and rescue use of 
intravenous NSAIDs (p = 0.12) among the three 
groups.  There were no significant differences in 
the median pain score at any PODs for the three 
groups (Fig. 3).  In the case of receiving the 
pharmacologic prophylaxis, postoperative pain 
control was through intravenous analgesia as a 
substitute for epidural anesthesia.  However, 
increases of postoperative analgesia use and 
postoperative pain score were not observed.
Plasma FDP and D-dimer levels on POD 7 in 
the high risk group were significantly lower than 
those in the highest (p < 0.01) and the low risk 
groups (p < 0.01) (Fig. 4).  There were no statistical 
the high risk groups were significantly higher 
than those of the low risk group (p < 0.0001). 
The patients selected for the pharmacological pro-
phylaxis were therefore confirmed as clinically high 
risk patients for VTE by the Caprini score.  In the 
Caprini score, postoperative anticoagulant therapy 
was recommended for the patients with 5 or more 
scores.  As a result, pharmacological prophylaxis 
was recommended in 142 cases (91.0%) in our 
study.  In the original classification, pharmacologi-
cal prophylaxis was recommended in the highest 
risk and the high risk patients (66 cases, 42.3%). 
This demonstrated that this classification was 
more selective as the pharmacological prophylaxis 
was reserved for the high risk patient of VTE, in 
order to minimize the adverse effect.
Patient characteristics and pharmacologic 
prophylaxis
Patient characteristics of the three groups are 
demonstrated in Table 3.  Among the three groups, 
there were no significant differences in sex (p = 
0.51) and body mass index (p = 0.48).  However, 
there were significant differences in the mean age 
(p < 0.01).  There were also significant differences 
in the mode of pain control (p < 0.01): intravenous 
analgesia was mainly performed in the high risk 
group and the highest risk group, and epidural 
anesthesia was mainly performed in the low risk 
group.
Actually, postoperative pharmacologic prophylaxis 
was applied for 59 cases (37.8%).  At the attending 
doctor’s discretion, seven cases were not adminis-
tered anticoagulant therapy because of the risk of 
postoperative bleeding, Continuous injection of UFH 
was applied in the highest risk group (14 cases) and 
subcutaneous injection of enoxaparin was applied in 
the high risk group (45 cases).  Median day of initia-
Table 3. Patient characteristics and postoperative courses in the three groups
Low risk
(n = 90)
High risk
(n = 50)
Highest risk
(n = 16) p-value
Sex Male / Female 49 / 41 32 / 18 10 / 6 0.51
Mean age (years old) (range) 65.0 (21 – 91) 68.5 (43 – 93) 78.3 (64 – 86) <0.01
Body mass index (median, range) 21.6 (14.5 – 29) 22.3 (15.7 – 34) 22.3 (17.1 – 27.8) 0.48
Analgesia (case) Epidural anesthesia/IV-PCA 77 / 13 6 / 43 0 / 16 <0.01
Postoperative outcomes
First flatus day (median, range) 2.4 (1 – 5) 2.1 (0 – 7) 2.6 (1 – 9) 0.37
First defecation day (median, range) 3.5 (1 – 7) 3.3 (1 –7) 3.8 (1 – 8) 0.54
Postoperative ambulation day (median, range) 3.3 (1 – 15) 3.8 (1 – 14) 4.6 (3 – 10) <0.01
Postoperative hospital stay (day, median, range) 13.0 (5 – 41) 16.7 (7 – 49) 17.6 (8 – 39) <0.01
Postoperative complications (G2 or more) (case) (%) 13 (14%) 15 (30%) 3 (19%) 0.08
Decline of hemoglobin levels (more than 2 g/dl) (case) (%) 2 (2%) 2 (4%) 0 (0%) 0.65
Administration of routine oral NSAIDs (case) (%) 27 (30%) 19 (38%) 3 (19%) 0.32
Rescue use of oral NSAIDs (time, median, range) 2.3 (0 –18) 2.3 (0 – 10) 2.3 (0 – 12) 0.90
Rescue use of intravenous NSAIDs (time, median, range) 2.3 (0 – 15) 1.7 (0 – 12) 1.2 (0 – 7) 0.12
IV-PCA, intravenous patient control analgesia; NSAIDs, Non-Steroidal Anti-Inflammatory Drugs
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DISCUSSION
In the present study, we tried to establish the 
original risk classification to determine the indica-
tion of pharmacological prophylaxis in selected pa-
tients at high risk of VTE in order to minimize 
the complications of pharmacological prophylaxis. 
This classification can lead to more selective phar-
macological prophylaxis than Caprini score and 
demonstrated the possible efficacy in the preven-
tion of postoperative VTE.
Pharmacologic prophylaxis after gastroentero-
logical surgery was not widely administrated, es-
pecially in Japan.  Historically, VTE has been 
considered to be a rare surgical complication in 
Japan, however, the incidence of VTE in general 
surgery appears to be increasing15).  The overall 
incidence of VTE has been reported to be 24.3% in 
Japanese patients, suggesting that pharmacologi-
cal prophylaxis is essential to prevent VTE16).  The 
other reasons were surgeons’ concerns about bleed-
ing complications and/or epidural hematoma after 
epidural anesthesia.  We thought, therefore, more 
selective pharmacologic prophylaxis was needed 
based on the risk classification that could identify 
the patients at high risk for VTE.  The present re-
sults showed that our established classification can 
lead to more selective pharmacological prophylaxis 
than previous criteria and guideline.  In this clas-
sification, low risk group patients did not receive 
pharmacological prophylaxis, however, some part 
of the low risk group patients are recommended 
pharmacological prophylaxis as per Caprini score 
and/or Japanese guideline.  Further investigation 
is mandatory whether such patients need to be on 
differences between FDP and D-dimer on POD 7 of 
the highest risk group and those of the low risk 
group (p = 0.47 and p = 0.45, respectively).  In ad-
dition, in the low risk group, FDP and D-dimer 
on POD 7 were significantly increased than those 
on POD 1 (p < 0.001 and p < 0.001, respectively), 
however, in the highest and the high risk group, 
there were no significant differences between FDP 
and D-dimer on POD 1 and those on POD 7 (p = 0.63 
and p = 0.39 in highest risk group, respectively, and 
p = 0.75 and p = 0.22 in high risk group, respective-
ly).  These results indicated the clinical significance 
of pharmacological prophylaxis in the view of these 
markers.
Fig. 3. Postoperative pain score of the three groups.
There were no significant differences in the median 
pain score at any postoperative days for three groups. 
VAS, visual analogue scale
Fig. 4. Postoperative kinetics of fibrin degradation products (FDP) (A) and D-dimer (B) in the three groups.
Plasma FDP and D-dimer levels on postoperative day 7 in the high risk group were significantly lower than those in 
the highest (p < 0.01) and the low risk groups (p < 0.01). All data are expressed as mean values ± standard deviation.
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after surgery2,18).  The Enoxaparin and Cancer II 
study has shown that, at least in high-risk pa-
tients, there is a significant benefit of an extended 
4-week prophylactic period compared with the 
standard 1-week regimen3).  The majority of pa-
tients who underwent gastroenterological surgery, 
were discharged one week after surgery, therefore, 
prolonged prophylaxis extending for several weeks 
may not be recommended for the Japanese popula-
tion in general.  In the present study, the duration of 
pharmacological prophylaxis was determined to be 7 
days; however, it was necessary to pay attention to 
the occurrence of VTE for several weeks after dis-
charge from the hospital.
In conclusion, our classification of VTE can lead 
to more selective application of the pharmacologic 
prophylaxis, to minimize the complications.  The 
efficacy in the prevention of postoperative VTE 
has also been demonstrated.  Further investiga-
tion is needed to evaluate the prophylactic effects 
in VTE.
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